Phthalimide conjugation as a strategy for in vivo target protein degradation

Cited by (1,004)

Items 801–900 of 1,004

1. Structure‐Based Design of a Macrocyclic PROTAC
   Andrea Testa, Scott J. Hughes, Xavier Lucas, Jane E. Wright, Alessio Ciulli · 2019 · Angewandte Chemie
2. Molecular glues: enhanced protein-protein interactions and cell proteome editing
   Evita G. Weagel, Jason M. Foulks, Adam Q. Siddiqui, Steven L. Warner · 2022 · Medicinal Chemistry Research
3. Small-Molecule PROTACs for Cancer Immunotherapy
   Zefan Liu, Yajun Zhang, Yucheng Xiang, Xin Kang · 2022 · Molecules
4. Quantitatively Predictable Control of Cellular Protein Levels through Proteasomal Degradation
   Wenting Zhao, Lara Pferdehirt, Laura Segatori · 2017 · ACS Synthetic Biology
5. The new direction of drug development: Degradation of undruggable targets through targeting chimera technology
   Xuewu Liang, Hairu Ren, Fengyang Han, Renwen Liang, Jiayan Zhao, Hong Shu Liu · 2023 · Medicinal Research Reviews
6. Covalent Degrader of the Oncogenic Transcription Factor β-Catenin
   Flor A. Gowans, Nafsika Forte, Justin Hatcher, Oscar W. Huang, Yangzhi Wang, Belen E. Altamirano Poblano, Ingrid E. Wertz, Daniel K. Nomura · 2024 · Journal of the American Chemical Society
7. Principles of paralog-specific targeted protein degradation engaging the C-degron E3 KLHDC2
   Daniel C. Scott, Suresh Dharuman, Elizabeth C. Griffith, Sergio C. Chai, Jarrid Ronnebaum, Moeko Toride King, Rajendra P. Tangallapally, Chan Lee, Clifford T. Gee, Lei Yang et al. · 2024 · Nature Communications
8. Indolequinone-Based Hypoxia-Activated Proteolysis Targeting Chimeras Selectively Degrade BRD4 in Hypoxic Cancer Cells
   M. Teresa Serafini, Sophie A. Twigger, George Delfas, Maxim Mallerman, Elliot P. Bailey, Ewen D. D. Calder, Ester M. Hammond, Stuart J. Conway · 2025 · Journal of the American Chemical Society
9. A FRET-Based Assay for the Identification and Characterization of Cereblon Ligands
   Iuliia Boichenko, Silvia Deiss, Kerstin Bär, Marcus D. Hartmann, Birte Hernandez Alvarez · 2016 · Journal of Medicinal Chemistry
10. Development of a Small Hybrid Molecule That Mediates Degradation of His-Tag Fused Proteins
    Koyo Okitsu, Takayuki Hattori, Takashi Misawa, Takuji Shoda, Masaaki Kurihara, Mikihiko Naito, Yosuke Demizu · 2017 · Journal of Medicinal Chemistry
11. Emerging Chemistry Strategies for Engineering Native Chromatin
    Yael David, Tom W. Muir · 2017 · Journal of the American Chemical Society
12. Targeting the E3 ubiquitin ligases DCAF15 and cereblon for cancer therapy
    Khai M. Nguyen, Luca Busino · 2020 · Seminars in Cancer Biology
13. Development of small-molecule BRD4 degraders based on pyrrolopyridone derivative
    Jian Zhang, Pan Chen, Peiyu Zhu, Peiyuan Zheng, Tao Wang, Lixun Wang, Changliang Xu, Jinpei Zhou, Huibin Zhang · 2020 · Bioorganic Chemistry
14. The application of ubiquitin ligases in the PROTAC drug design
    Yilin Chen, Jianping Jin · 2020 · Acta Biochimica et Biophysica Sinica
15. Bromodomain protein BRDT directs ΔNp63 function and super-enhancer activity in a subset of esophageal squamous cell carcinomas
    Xin Wang, A. Kutschat, M. Yamada, E. Prokakis, Patricia Böttcher, Koji Tanaka, Y. Doki, F. Hamdan, S. Johnsen · 2021 · Cell Death and Differentiation
16. Molecular Mechanisms of Cereblon-Interacting Small Molecules in Multiple Myeloma Therapy
    Matteo Costacurta, Jackson He, Philip Evan Thompson, Jake Shortt · 2021 · Journal of Personalized Medicine
17. Recent advances in induced proximity modalities
    Christine S.C. Ng, Steven M. Banik · 2022 · Current Opinion in Chemical Biology
18. (mis)-Targeting of SWI/SNF complex(es) in cancer
    Divya Reddy, Saikat Bhattacharya, Jerry L. Workman · 2023 · Cancer and Metastasis Reviews
19. DLBCL-associated NOTCH2 mutations escape ubiquitin-dependent degradation and promote chemoresistance
    Nan Zhou, Jaewoo Choi, Grant P. Grothusen, Bang‐Jin Kim, Diqiu Ren, Zhendong Cao, Yiman Liu, Qinglan Li, Arati A. Inamdar, Thomas Beer et al. · 2023 · Blood
20. Targeted therapy for fusion-driven high-risk acute leukemia
    Yana Pikman, Kimberly Stegmaier · 2018 · Blood
21. Emerging TACnology: Heterobifunctional Small Molecule Inducers of Targeted Posttranslational Protein Modifications
    Pascal Heitel · 2023 · Molecules
22. PROTAC unleashed: Unveiling the synthetic approaches and potential therapeutic applications
    Narayanaperumal Pravin, Krzysztof Jóźwiak · 2024 · European Journal of Medicinal Chemistry
23. Discovery of ERD-12310A as an Exceptionally Potent and Orally Efficacious PROTAC Degrader of Estrogen Receptor α (ERα)
    Rohan Kalyan Rej, Biao Hu, Zhixiang Chen, Ranjan Kumar Acharyya, Dimin Wu, Hoda Metwally, Donna McEachern, Yu Wang, Wei Jiang, Longchuan Bai et al. · 2024 · Journal of Medicinal Chemistry
24. Strategy and Design of In Situ Activated Protein Hydrolysis Targeted Chimeras
    Mei-Yu Lv, Da‐Yong Hou, Shaowei Liu, Dong‐Bing Cheng, Haoran Wang · 2024 · ACS Nano
25. Emerging modes-of-action in drug discovery
    Eric Valeur, Frank Narjes, Christian Ottmann, Alleyn T. Plowright · 2019 · MedChemComm
26. Discovery of [1,2,4]triazolo[1,5-a]pyrimidine derivatives as new bromodomain-containing protein 4 (BRD4) inhibitors
    Shuai Wang, Dandan Shen, Lijie Zhao, Xiaohan Yuan, Jialing Cheng, Bin Yu, Yi‐Chao Zheng, Hong‐Min Liu · 2019 · Chinese Chemical Letters
27. Photopharmacology of Proteolysis-Targeting Chimeras: A New Frontier for Drug Discovery
    Shenxin Zeng, Hongjie Zhang, Zhengrong Shen, Wenhai Huang · 2021 · Frontiers in Chemistry
28. Selective degradation-inducing probes for studying cereblon (CRBN) biology
    Chelsea E. Powell, Guangyan Du, Jonathan W. Bushman, Zhixiang He, Tinghu Zhang, Eric S. Fischer, Nathanael S. Gray · 2021 · RSC Medicinal Chemistry
29. Bispecific Aptamer Chimeras Enable Targeted Protein Degradation on Cell Membranes
    Yanyan Miao, Qianqian Gao, Menghan Mao, Chao Zhang, Liqun Yang, Yang Yang, Da Han · 2021 · Angewandte Chemie
30. BRD4 degradation blocks expression of MYC and multiple forms of stem cell resistance in Ph+ chronic myeloid leukemia
    Barbara Peter, Gregor Eisenwort, Irina Sadovnik, Karin Bauer, Michael Willmann, Thomas Rülicke, Daniela Berger, Gabriele Stefanzl, Georg Greiner, Gregor Hoermann et al. · 2022 · American Journal of Hematology
31. PROTACs in gastrointestinal cancers
    Yu Chen, Qingfan Yang, Jinrun Xu, Liyao Tang, Yan Zhang, Fukuan Du, Yueshui Zhao, Xu Wu, Mingxing Li, Jing Shen et al. · 2022 · Molecular Therapy — Oncolytics
32. Screening of an epigenetic compound library identifies BRD4 as a potential antiviral target for hepatitis B virus covalently closed circular DNA transcription
    Xiaoyang Yu, Quanxin Long, Sheng Shen, Zhentao Liu, Jithin Chandran, Junjie Zhang, Hao Ding, Hu Zhang, Dawei Cai, Elena S. Kim et al. · 2023 · Antiviral Research
33. Reversible Assembly of Proteolysis Targeting Chimeras
    Weijun Gui, Sarah F. Giardina, Madeline Balzarini, Francis Barany, Thomas J. Kodadek · 2023 · ACS Chemical Biology
34. Modulares PROTAC‐Design zum Abbau von onkogenem BCR‐ABL
    Ashton C. Lai, Momar Toure, Doris Hellerschmied, Jemilat Salami, Saul Jaime‐Figueroa, Eunhwa Ko, John F. Hines, Craig M. Crews · 2015 · Angewandte Chemie
35. Chemical probes targeting epigenetic proteins: Applications beyond oncology
    Suzanne Z. Ackloo, Peter J. Brown, Susanne Müller · 2017 · Epigenetics
36. Bromodomain and BET family proteins as epigenetic targets in cancer therapy: their degradation, present drugs, and possible PROTACs
    Mohd. Muddassir, Kunjal V. Soni, Chetan B. Sangani, Abdullah Saad AlArifi, Mohd Faiz Afzal, Naaser A. Y. Abduh, Yongtao Duan, Poonam Bhadja · 2020 · RSC Advances
37. Elucidation of genome-wide understudied proteins targeted by PROTAC-induced degradation using interpretable machine learning
    Xie, Li, Xie, Lei · 2023 · PLOS Computational Biology
38. Breaking Bad Proteins—Discovery Approaches and the Road to Clinic for Degraders
    Corentin Bouvier, Rachel Lawrence, Francesca Cavallo, Wendy Xolalpa, Allan Michael Jordan, Roland Hjerpe, Manuel S. Rodríguez · 2024 · Cells
39. Discovery of a Natural Ent-Kaurene Diterpenoid Oridonin as an E3 Ligase Recruiter for PROTACs
    Jie Huang, Xuekun Fu, Fang Qiu, Zhijian Liang, Chunhao Cao, Zhuqian Wang, Hongzhen Chen, Siran Yue, Duoli Xie, Yiying Liang et al. · 2024 · Journal of the American Chemical Society
40. Advances in KEAP1-based PROTACs as emerging therapeutic modalities: Structural basis and progress
    Jing Chen, Disheng Feng, Rui Zhu, Hua Li, Lixia Chen · 2025 · Redox Biology
41. Epigenetic therapies in heart failure
    Michael Alexanian, Arun Padmanabhan, Timothy A. McKinsey, Saptarsi M. Haldar · 2019 · Journal of Molecular and Cellular Cardiology
42. The Molecular ‘Myc-anisms’ behind Myc-Driven Tumorigenesis and the Relevant Myc-Directed Therapeutics
    Jessica McAnulty, Analisa V. DiFeo · 2020 · International Journal of Molecular Sciences
43. Development of Rapid and Facile Solid‐Phase Synthesis of PROTACs via a Variety of Binding Styles
    Hanqiao Xu, Takashi Kurohara, Reina Takano, Hidetomo Yokoo, Norihito Shibata, Nobumichi Ohoka, Takao Inoué, Mikihiko Naito, Yosuke Demizu · 2022 · ChemistryOpen
44. Chemical genetics approaches for selective intervention in epigenetics
    Andrew C. Runcie, Kwok-Ho Chan, Michael Zengerle, Alessio Ciulli · 2016 · Current Opinion in Chemical Biology
45. Targeting Epidermal Growth Factor Receptor in Non-Small-Cell-Lung Cancer: Current State and Future Perspective
    Shui-Ming Bao, Qinghui Hu, Wen-Ting Yang, Yao Wang, Yin-Ping Tong, Wen-Dai Bao · 2019 · Anti-Cancer Agents in Medicinal Chemistry
46. A Pipeline for Drug Target Identification and Validation
    Eusebio Manchado, Chun‐Hao Huang, Nilgun Tasdemir, Darjus Felix Tschaharganeh, John Erby Wilkinson, Scott W. Lowe · 2016 · Cold Spring Harbor Symposia on Quantitative Biology
47. Conditional PROTAC: Recent Strategies for Modulating Targeted Protein Degradation
    Junhyeong Yim, Jun‐Young Park, Gabin Kim, Hyung Ho Lee, Jin Soo Chung, Ala Jo, Minseob Koh, Jongmin Park · 2024 · ChemMedChem
48. The anti‐mitotic agents PTC‐028 and PTC596 display potent activity in pre‐clinical models of multiple myeloma but challenge the role of BMI‐1 as an essential tumour gene
    Arnold Bolomsky, Joséphine Muller, Kathrin Stangelberger, Margaux Lejeune, Elodie Duray, Helene Breid, Louise Vrancken, Christina Pfeiffer, Wolfgang Hübl, Martin Willheim et al. · 2020 · British Journal of Haematology
49. Protein Ligand Interactions Using Surface Plasmon Resonance
    Nichole O’Connell · 2021 · Methods in molecular biology
50. Monobodies as tool biologics for accelerating target validation and druggable site discovery
    Padma Akkapeddi, Kai Wen Teng, Shohei Koide · 2021 · RSC Medicinal Chemistry
51. Redefining the Scope of Targeted Protein Degradation: Translational Opportunities in Hijacking the Autophagy–Lysosome Pathway
    Katelyn B. Cassidy, Heng Zhao · 2021 · Biochemistry
52. Translating PROTAC chemical series optimization into functional outcomes underlying BRD7 and BRD9 protein degradation
    Kristin M. Riching, James D. Vasta, Scott J. Hughes, Vittoria Zoppi, Chiara Maniaci, Andrea Testa, Marjeta Urh, Alessio Ciulli, Danette L. Daniels · 2021 · Current Research in Chemical Biology
53. Recent advances in synthetic glycoengineering for biological applications
    Yue Zeng, Feng Tang, Wei Shi, Qian Dong, Wei Huang · 2022 · Current Opinion in Biotechnology
54. Emerging roles of BET proteins in transcription and co‐transcriptional RNA processing
    Nicole Eischer, Mirjam Arnold, Andreas Mayer · 2022 · Wiley Interdisciplinary Reviews - RNA
55. ELIOT : A platform to navigate the E3 pocketome and aid the design of new PROTACs
    Tommaso Palomba, Massimo Baroni, Simon Cross, Gabriele Cruciani, Lydia Siragusa · 2022 · Chemical Biology & Drug Design
56. A high affinity pan-PI3K binding module supports selective targeted protein degradation of PI3Kα
    Werner Theodor Jauslin, Matthias Schild, Thorsten Schaefer, Chiara Borsari, Clara Orbegozo, Lukas Bissegger, Saule Zhanybekova, Danilo Ritz, Alexander Schmidt, Matthias P. Wymann et al. · 2023 · Chemical Science
57. PROTAC: Novel degradable approach for different targets to treat breast cancer
    Zhenjie Wang, Siyao Che, Zhiqiang Yu · 2024 · European Journal of Pharmaceutical Sciences
58. Pharmacologic Targeting of Chromatin Modulators As Therapeutics of Acute Myeloid Leukemia
    Rui Lu, Gang Greg Wang · 2017 · Frontiers in Oncology
59. Macrocyclic Peptides Closed by a Thioether–Bipyridyl Unit That Grants Cell Membrane Permeability
    Hongxue Chen, Takayuki Katoh, Hiroaki Suga · 2023 · ACS Bio & Med Chem Au
60. Recent insights of PROTAC developments in inflammation-mediated and autoimmune targets: a critical review
    Mary Sravani Galla, Nitika Sharma, Priyanka Mishra, Nagula Shankaraiah · 2024 · RSC Medicinal Chemistry
61. BRD4 degraders may effectively counteract therapeutic resistance of leukemic stem cells in AML and ALL
    Karin Bauer, Alexander W. Hauswirth, Karoline Veronika Gleixner, Georg Greiner, J. Thaler, Peter Bettelheim, Yüksel Filik, Elisabeth Koller, Gregor Hoermann, Philipp Bernhard Staber et al. · 2024 · American Journal of Hematology
62. Recent advances in dual PROTACs degrader strategies for disease treatment
    Jianyu Liu, Yanzhuo Liu, Jiao Tang, Qianyuan Gong, Guoyi Yan, Hengrui Fan, Xueping Zhang, Chunlan Pu · 2024 · European Journal of Medicinal Chemistry
63. Prodrug Strategy for PROTACs: High Efficiency and Low Toxicity
    Yuqing Li, Yongcheng Guo, Simin Ma, Baobang Long, Rui Kong, Xin Huang, Kun Zhao, Ying Zhi · 2025 · ACS Omega
64. Discovery of a bifunctional PKMYT1-targeting PROTAC empowered by AI-generation
    Yazhou Wang, Xiaomin Wang, Tingting Liu, Chao Wang, Qingshuo Meng, Fanye Meng, Jiaojiao Yu, Jinxin Liu, Yaya Fan, David G. Gennert et al. · 2025 · Nature Communications
65. Organocatalyzed Synthesis of Highly Functionalized Phthalimides via Diels–Alder Reaction Employing Two Dienophiles
    Muhammad Saeed Akhtar, Yong Rok Lee · 2020 · The Journal of Organic Chemistry
66. Design, Synthesis and In Vitro Investigation of Cabozantinib-Based PROTACs to Target c-Met Kinase
    Anastasia A. Sachkova, Daria V. Andreeva, Alexander S. Tikhomirov, Alexander Mikhailovich Scherbakov, Diana I. Salnikova, Danila Vladimirovich Sorokin, Fedor B. Bogdanov, Yulia D. Rysina, Andrey Egorovich Shchekotikhin, Ekaterina S. Shchegravina et al. · 2022 · Pharmaceutics
67. Clinical Efficacy of a Novel Therapeutic Principle, Anakoinosis
    Daniel Heudobler, Michael Rechenmacher, Florian Lüke, Martin Vogelhuber, Sebastian Klobuch, Simone Thomas, Tobias Pukrop, Christina Hackl, Wolfgang Herr, Lina Ghibelli et al. · 2018 · Frontiers in Pharmacology
68. Degradation of BRD4 - a promising treatment approach not only for hematologic but also for solid cancer.
    Karin Bauer, Anna Sophie Berghoff, Matthias Preusser, Gerwin Heller, Christoph Carl Zielinski, Peter Valent, Thomas W. Grunt · 2021 · PubMed Central
69. Proteome-scale induced proximity screens reveal highly potent protein degraders and stabilizers
    Juline Poirson, Akashdeep Dhillon, Hanna Cho, Mandy Hiu Yi Lam, Nader Alerasool, Jessica Lacoste, Lamisa Mizan, Mikko Taipale · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
70. Advances in designing ternary complexes: Integrating in-silico and biochemical methods for PROTAC optimisation in target protein degradation
    Shareef Shaik, Prasanna Kumar Reddy Gayam, Manish Chaudhary, Gurvinder Singh, Aravinda Pai · 2024 · Bioorganic Chemistry
71. An engineered cereblon optimized for high-throughput screening and molecular glue discovery
    H. Bailey, Jonathan Eisert, Rubina S. Kazi, Jan Gerhartz, Dominika Ewa Pieńkowska, Ina Dressel, Joshua Vollrath, Ivan S. Kondratov, Tetiana Matviiuk, Nataliya A. Tolmachova et al. · 2024 · Cell chemical biology
72. PROTAC-induced protein structural dynamics in targeted protein degradation
    Kingsley Y Wu, Ta I Hung, Chia‐en A. Chang · 2025 · eLife
73. Design of PROTACs utilizing the E3 ligase GID4 for targeted protein degradation
    Yanran Li, Kaiwen Bao, Jiyue Sun, Ruixin Ge, Qiqing Zhang, Bing Zhang, Xiaojie Yan, Junlin Li, Fengying Shi, Meiling Zhang et al. · 2025 · Nature Structural & Molecular Biology
74. PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degraders for Treatment of Estrogen Receptor–Positive Advanced Breast Cancer
    Erika Paige Hamilton, Rinath M. Jeselsohn, Linda T. Vahdat, Sara Alsterlind Hurvitz · 2025 · Targeted Oncology
75. Proteolysis‐targeting chimeras in cancer therapy: Targeted protein degradation for next‐generation treatment
    Yamile Abuchard Anaya, Mariana Barragan, Ricardo Pequeno Bracho, Salique H. Shaham, Debasish Bandyopadhyay, Elias George, Diane Duyen Thuy Nguyen, Manish Kumar Tripathi · 2025 · Cancer
76. Direct-to-Biology Enabled Molecular Glue Discovery
    Maowei Hu, Jason Ochoada, Marisa Actis, Kevin M. McGowan, Jamie Jarusiewicz, Satoshi Yoshimura, Logan McGrath, Uma Neelakantan, Anup Aggarwal, Anand Mayasundari et al. · 2025 · Journal of the American Chemical Society
77. Proteolysis targeting chimera technology: a novel strategy for treating diseases of the central nervous system
    Ke Ma, Xiao-Xiao Han, Xiaoxiao Han, Songlin Zhou · 2021 · Neural Regeneration Research
78. Proteolysis-Targeting Chimera (PROTAC): Is the Technology Looking at the Treatment of Brain Tumors?
    Ludovica Lospinoso Severini, Francesca Bufalieri, Paola Infante, Lucia Di Marcotullio · 2022 · Frontiers in Cell and Developmental Biology
79. Targeting bromodomain and extra-terminal proteins to inhibit neuroblastoma tumorigenesis through regulating MYCN
    Xiyao Shi, Ying Wang, Longhui Zhang, Wenjie Zhao, Xiangpeng Dai, Yong‐Guang Yang, Xiaoling Zhang · 2022 · Frontiers in Cell and Developmental Biology
80. Development of Gilteritinib-Based Chimeric Small Molecules that Potently Induce Degradation of FLT3-ITD Protein
    Nobumichi Ohoka, Masanori Suzuki, Takuya Uchida, Genichiro Tsuji, Yoshinori Tsukumo, Masayuki Yoshida, Takao Inoué, Yosuke Demizu, Hitoshi Ohki, Mikihiko Naito · 2022 · ACS Medicinal Chemistry Letters
81. Innovative, combinatorial and high-throughput approaches to degrader synthesis
    Rebecca Stevens, James D. F. Thompson, Julie C. L. Fournier, Glenn A. Burley, David J. Battersby, Afjal H. Miah · 2024 · Chemical Society Reviews
82. Degradation of the BAF Complex Factor BRD9 by Heterobifunctional Ligands
    David Remillard, Dennis L. Buckley, Joshiawa Paulk, Gerard L. Brien, Matthew Sonnett, Hyuk‐Soo Seo, Shiva Dastjerdi, Martin Wühr, Sirano Dhe‐Paganon, Scott A. Armstrong et al. · 2017 · Angewandte Chemie
83. M1/M2 macrophage-targeted nanotechnology and PROTAC for the treatment of atherosclerosis
    Yupeng Ma, Xiaofan Yang, Ke Ning, Haidong Guo · 2024 · Life Sciences
84. Controlled bioorthogonal activation of Bromodomain-containing protein 4 degrader by co-delivery of PROTAC and Pd-catalyst for tumor-specific therapy
    Zhiyao Li, Tai‐Bai Jiang, Yuan Xu, Bowen Li, Chongzhi Wu, Yecheng Li, Yong Ping Huang, Xin Xie, Weidong Pan, Ping Yuan · 2024 · Journal of Controlled Release
85. Advancing Design Strategy of PROTACs for Cancer Therapy
    Hang Luo, Yuan Tian, Razack Abdullah, Bao‐Ting Zhang, Yuan Ma, Ge Zhang · 2025 · MedComm
86. Synthesis, biological evaluation and clinical trials of Cereblon-based PROTACs
    André T. S. Vicente, Sara P. S. P. Moura, Jorge A. R. Salvador · 2025 · Communications Chemistry
87. Global landscape of PROTAC: Perspectives from patents, drug pipelines, clinical trials, and licensing transactions
    Hong Xin Cai, Tianyi Zhang, Hu Yuanjia · 2025 · European Journal of Medicinal Chemistry
88. Design, Synthesis, and Biological Evaluation of Proteolysis Targeting Chimeras (PROTACs) for the Dual Degradation of IGF-1R and Src
    Sudhakar Manda, Na Keum Lee, Dong‐Chan Oh, Jeeyeon Lee · 2020 · Molecules
89. Cereblon harnesses Myc-dependent bioenergetics and activity of CD8+ T lymphocytes
    Rebecca S. Hesterberg, Matthew S. Beatty, Ying Han, Mario R. Fernandez, Afua Adutwumwa Akuffo, William E. Goodheart, Chunying Yang, Shiun Chang, Christelle Colin, Aileen Y. Alontaga et al. · 2020 · Blood
90. General Stepwise Approach to Optimize a TR-FRET Assay for Characterizing the BRD/PROTAC/CRBN Ternary Complex
    Wenwei Lin, Taosheng Chen · 2021 · ACS Pharmacology & Translational Science
91. Proteolysis-Targeting Chimeras Enhance T Cell Bispecific Antibody-Driven T Cell Activation and Effector Function through Increased MHC Class I Antigen Presentation in Cancer Cells
    Vittoria Massafra, Sofia Tundo, Aline Dietzig, Axel Ducret, Christian Jöst, Christian Klein, Roland E. Kontermann, Hendrik Knoetgen, Martin Steegmaier, Andrea Romagnani et al. · 2021 · The Journal of Immunology
92. BET in hematologic tumors: Immunity, pathogenesis, clinical trials and drug combinations
    Tao Ma, Yan Chen, Zhigang Yi, Yanhong Li, Jun Yuan Bai, Lijuan Li, Liansheng Zhang · 2022 · Genes & Diseases
93. Design, synthesis, and biological evaluation of BRD4 degraders
    Mengyuan Ding, Ying-Ying Shao, Danwen Sun, Suorina Meng, Yi Zang, Yubo Zhou, Jia Xuan Li, Wei Ping Lu, Shulei Zhu · 2022 · Bioorganic & Medicinal Chemistry
94. Targeting phosphatases: From molecule design to clinical trials
    Mochen Guo, Zekun Li, Mingxiao Gu, Junrui Gu, Qidong You, Lei Wang · 2023 · European Journal of Medicinal Chemistry
95. Alkenyl oxindole is a novel PROTAC moiety that recruits the CRL4DCAF11 E3 ubiquitin ligase complex for targeted protein degradation
    Ying Wang, Tianzi Wei, Man Zhao, Aima Huang, Fan Sun, Lu Chen, Risheng Lin, Yubao Xie, Ming Zhang, Shiyu Xu et al. · 2024 · PLoS Biology
96. Pooled endogenous protein tagging and recruitment for systematic profiling of protein function
    Yevgeniy V. Serebrenik, D.R. Mani, Timothé Maujean, George M. Burslem, Ophir Shalem · 2024 · Cell Genomics
97. Induced degradation of protein kinases by bifunctional small molecules: a next-generation strategy
    Jay Clemens Groppe · 2019 · Expert Opinion on Drug Discovery
98. Degradation of intracellular TGF-β1 by PROTACs efficiently reverses M2 macrophage induced malignant pathological events
    Yanqiao Feng, Hui Su, Yunzhi Li, Chunxiang Luo, Huiying Xu, Youqiao Wang, Haixia Sun, Guohui Wan, Binhua Zhou, Xianzhang Bu · 2020 · Chemical Communications
99. Selective Degradation of Target Proteins by Chimeric Small-Molecular Drugs, PROTACs and SNIPERs
    Minoru Ishikawa, Shusuke Tomoshige, Yosuke Demizu, Mikihiko Naito · 2020 · Pharmaceuticals
100. Targeted modulation of E3 ligases using engineered ubiquitin variants
     Nicole LeBlanc, Evan Mallette, Wei Zhang · 2020 · FEBS Journal